Altuviiio May See Rapid Uptake Upon European Approval In Hemophilia A
Pediatric Data Clears Path For EMA Filing
Executive Summary
Sanofi announced results from its XTEND-Kids trial, clearing the last requirement before an anticipated second half filing for Altuviiio’s approval with the EMA.
You may also be interested in...
Sanofi’s Altuviiio Set To Reenergize Factor VIII Space
The once-weekly Factor VIII replacement therapy for hemophilia A, newly approved by the US FDA, appears well positioned to compete with Roche’s blockbuster Hemlibra.
Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success
Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.
Unity’s UBX1325 Faces Uncertain Path Forward In AMD, But DME Still Looks Promising
The company said the Phase II ENVISION study of the drug in wet age-related macular degeneration did not show non-inferiority to Eylea, leaving it with an uncertain path forward in that indication.